TScan Therapeutics Announces $30 Million Registered Direct OfferingOn December 26, 2024, TScan Therapeutics, Inc. (NASDAQ: TCRX) entered into a securities purchase agreement with Lynx1 Capital Management LP, an existing shareholder, and an investment
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read TScan Therapeutics’s 8K filing here. TScan Therapeutics Company Profile (Get Free Report) TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients […]
More Stories
When Your Payment Provider Can No Longer Keep Up
A payment account can work perfectly well until the business starts growing. Sales rise and customers arrive from new countries,...
The Hawk Season 2 Updates: Where Did Season 1 End
Netflix’s 2026 series, The Hawk, has been released. It has received a mixed response from the audience in different parts...
Netflix’s Upcoming Sports Documentary: Mourinho Is Releasing Soon
Football fans, be ready! Netflix is about to drop one of its most-awaited sports documentaries of 2026. Mourinho is a...
Order of the Sinking Star is Ready to Launch on PlayStation 5 and TV
The creator of Braid and The Witness, Jonathan Blow, is returning with an all-new puzzle video game, Order of the...
Netflix’s Upcoming Drama, All the Truth in My Lies: Release Date, Cast, and More
Excited to know about the upcoming Spanish drama on Netflix, All the Truth in My Lies. If you love watching...
Obsession (2026): Release Date, Cast Members, Trailer, Plot, and More
Be Alert: Spoilers Ahead! Are you also a lover of horror shows and looking for upcoming horror movies and series...